Caris Life Sciences focuses on molecular profiling and precision oncology diagnostics, analyzing tumor tissue and blood to characterize cancer at the molecular level. Its testing helps physicians match patients to targeted therapies, clinical trials and treatment strategies based on comprehensive genomic and other molecular data. The company serves oncologists, health systems and biopharma partners that need detailed tumor intelligence for personalized care and drug development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 181.4 | — | -517.2 | — |
| Q3 2025 | 216.8 | — | 24.3 | — |
| Q4 2025 | 292.9 | — | 82 | — |
| Q1 2026 | 216.2 | — | -0.5 | — |
| Q2 2026 | 263.7 | 45.4% | -0.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Cytokinetics, Incorporated (CYTK), Chord Energy Corporation (CHRD), Hut 8 Corp. (HUT), Bruker Corporation (BRKR), Protagonist Therapeutics, Inc. (PTGX), Lineage, Inc. (LINE)